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Metastatic bone disease is a common manifestation of
advanced cancers with a very high prevalence in breast,
prostate and lung cancers. In order to effectively manage
patients with metastatic bony disease it is essential to
have consistent, reproducible and validated methods for
detecting and assessing the response to therapy. In
response assessments, confident categorization of
response is needed to enable therapeutic strategies to be
tailored to individual patient’s benefit. Commonly used
methods such as x-rays, bone and CT scans do not
always enable the positive assessment of therapeutic
benefit to be made but instead provide an evaluation of
progression, which then guides therapy decisions in the
clinic.
Whole body MRI incorporating DW imaging
(WB-DWI) has emerged as a promising bone marrow
assessment tool [1] for detection [2,3] and therapy
monitoring of bone metastases [4]. On WB-DWI, lytic/
infiltrative skeletal metastases appear as focal or diffuse
areas of high-signal intensity on high b-values on a back-
ground of lower signal intensity of the normal bone mar-
row [4,5]. Metastasis detection with DWI should be done
with anatomical MRI [1,4,5]; a recent meta-analysis
demonstrated high sensitivity of WB-DWI to detect
metastases at the expense of specificity [2]. Causes for
false-positive findings on WB-DWI include bone marrow
oedema, vertebral haemangioma, isolated bone marrow
islands and bone marrow hyperplasia. False-negative
findings occur when there are low levels of bone marrow
infiltration or when background bone marrow hyperplasia
obscures metastases. Detection of skeletal metastases may
be impaired in areas of body movement and the visibility
of skull base infiltrations is impaired because of the adja-
cent high signal of the brain. False-negative findings also
include treated malignant disease and sclerotic deposits.
WB-DWI when combined with emerging “wet” bio-
markers can improve the classification of therapy
response in patients with metastatic bone disease. Both
high b-value image signal intensity and ADC value
changes are needed for therapeutic assessments [4,5].
A range of imaging findings can be seen depending on
the type of therapy and duration of treatment [4].
Morphologic and diffusion MRI therapy response criteria
need to be tested in prospective studies in order to
address current, unmet clinical and pharmaceutical needs
for reliable measures of tumor response in metastatic
bone disease [5].
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